Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours
Endocrine Oncology · 01.01.2025 · 5 (1)
DOI: 10.1530/eo-25-0005 ↗Kurz gefasst
Fallbericht in der Zeitschrift Endocrine Oncology, online erschienen am 03.07.2025. Verfasst von Isuru Gamage und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Somatostatin analogues (SSA) are used in the management of patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) to control hormone secretion and tumour growth. SSA can paradoxically worsen or unmask hypoglycaemia in patients with insulinoma by inhibiting counter-regulatory hormones such as glucagon and growth hormone. Design and methods We present two cases of SSA use in patients with initially presumed non-functioning GEP-NET unmasking insulinoma. We review the use of SSA in GEP-NET and the management of refractory hypoglycaemia in metastatic insulinoma.
Results
A 62-year-old female with metastatic grade 2 GEP-NET was commenced on monthly lanreotide 10 weeks after diagnosis. She presented 1 week following the second dose with refractory hypoglycaemia and inappropriate hyperinsulinism, requiring inpatient dextrose infusion. SSA was stopped; however, she remained dextrose dependent despite the addition of diazoxide and dexamethasone. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-Octreotate was given, resulting in resolution of hypoglycaemia after two cycles. The second case is a 57-year-old female with metastatic grade 2 GEP-NET. Four months post commencement of lanreotide, she presented with radiological disease progression and symptomatic hypoglycaemia. A 72 h fast confirmed hyperinsulinaemic hypoglycaemia. SSA was stopped. A trial of diazoxide was not tolerated, and a prednisolone trial was ineffective. The patient underwent inpatient PRRT with euglycaemia achieved shortly afterwards.
Conclusions
SSA can unmask hypoglycaemia secondary to insulinoma. Detection of new-onset hypoglycaemia requires careful clinical vigilance when commencing SSA in patients with GEP-NET initially presumed to be non-functional. Hypoglycaemia from metastatic insulinoma requires multidisciplinary management incorporating nutritional, medical and oncologic therapy. PRRT can be effective in managing refractory hypoglycaemia. Learning points
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
- ENETS Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Centre Melbourne, Melbourne, Australia.
- Department of Clinical Pathology, Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne, Melbourne, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
ORCID-Profile: Isuru Gamage, Emma Boehm
Zitieren
APA
Gamage, I., Boehm, E., Ghosh, G., Kong, G., Michael, M., Wong, H., Piercey, O., & Sachithanandan, N. (2025). Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours. Endocrine Oncology, 5(1). https://doi.org/10.1530/eo-25-0005
Vancouver
Gamage I, Boehm E, Ghosh G, Kong G, Michael M, Wong H, et al. Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours. Endocrine Oncology. 2025;5(1). doi:10.1530/eo-25-0005
BibTeX
@article{Gamage2025,
author = {Gamage, Isuru and Boehm, Emma and Ghosh, Gaurav and Kong, Grace and Michael, Michael and Wong, HuiLi and Piercey, Oliver and Sachithanandan, Nirupa},
title = {Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours},
journal = {Endocrine Oncology},
year = {2025},
volume = {5},
number = {1},
doi = {10.1530/eo-25-0005}
}
EUVIMED